NYSE American: RGNT · Listed Dec 4, 2025
Regentis Biomaterials IPO
IPO price
$8.00
Regentis Biomaterials (RGNT) priced its IPO at $8.00 a share and has traded on NYSE American since Dec 4, 2025.
RGNT today$1.18-85.25%since IPO15-min delayed · as of 4:40:06 AM EST on Nov 19, 2026
See the RGNT quoteFirst trading day · Dec 4, 2025
- IPO price
- $8.00
- below the range of $10 to $12
- First trade
- $7.40
- -7.50% from the IPO price
- First-day last trade
- $7.25
- -9.38% from the IPO price, regular session
- Raise
- $10M
- before the underwriters' option
These numbers are from the first trading day, Dec 4, 2025.
How RGNT did against the market
RGNT against the market, from its first trade at 10:50 ET to the last trade of the session.
- RGNT from its first trade
- -2.03%
- Against the market (QQQ)
- -2.1 pts
RGNT fell 2.0% from its first trade to the last trade of the session. That is 2.1 points worse than the market.
Same-day moves do not show that RGNT caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
RGNT against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
RGNT against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Regentis Biomaterials '25 | $10M | -7.50% | -9.38% | -11.25% | -13.50% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Regentis Biomaterials IPO offers 1.25M shares to raise $10M, before any underwriters' option.
- Expected price range
- $10 to $12
- IPO price
- $8.00
- Shares offered
- 1.25M
- Money raised
- $10M
- Listing date
- Dec 4, 2025
- Exchange
- NYSE American
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Regentis Biomaterials$10M
Where RGNT ranks
Regentis Biomaterials's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- RGNT$8.01M
RGNT news
The latest news and headlines about Regentis Biomaterials (RGNT).
- Regentis Biomaterials Slips 9% After Soaring 506% On Monday — Here's Why RGNT Stock Is TrendingnegativeBenzinga· Jun 16, 2026
- Regentis Biomaterials Ltd. Announces Closing of Initial Public OfferingpositiveBenzinga· Dec 5, 2025
Filings and the company
What Regentis Biomaterials has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Regentis Biomaterials discloses to the SEC on Form 8-K.
No 8-K filings yet. A filing appears here after Regentis Biomaterials files it with the SEC.
About Regentis Biomaterials
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
- Ticker
- RGNT
- Exchange
- NYSE American
- Market
- stocks
- Type
- CS
- Currency
- USD
- Employees
- 8
- Listed
- Dec 4, 2025
- Security
- Ordinary Shares
Frequently asked questions
What was the Regentis Biomaterials IPO price?
$8.00 a share.
When did Regentis Biomaterials go public?
Regentis Biomaterials listed on NYSE American on Dec 4, 2025 under the ticker RGNT.
How much did the Regentis Biomaterials IPO raise?
$10M, before any underwriters' option.
How did Regentis Biomaterials open on its first day?
RGNT first traded at $7.40, -7.50% from the IPO price of $8.00.
How did RGNT close on its first day?
Its last regular-session trade was $7.25, -9.38% from the IPO price of $8.00.
What was the RGNT first-day trading range?
$6.96 to $7.50 in the regular session.
How many RGNT shares traded on the first day?
314.29K shares in the regular session.
How many shares did Regentis Biomaterials sell in its IPO?
1.25M shares.
How did RGNT do against the market on its first day?
RGNT fell 2.0% from its first trade to the last trade of the session. That is 2.1 points worse than the market (QQQ, the Nasdaq-100 ETF).
What exchange is RGNT listed on?
Regentis Biomaterials lists on NYSE American under the ticker RGNT.
Build with Massive
Get the RGNT data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/RGNT/range/5/minute |
| Market cap | /v3/reference/tickers/RGNT |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.